Top NYC, NY Biotech Companies With Best Stability & Growth (222)

Investor Backing & Capital Strength: Recent financing includes a $50 million Series D anchored by Boehringer Ingelheim, following a Series C in 2025 and prior debt financing, indicating sustained access to strategic capital. The transfer of CT-155 commercialization responsibility alongside dedicated commercial funding further underscores capital support aligned with near-term growth plans.

Strategic Partnerships: Collaborations with major pharmaceutical companies such as Otsuka and Boehringer Ingelheim, alongside agreements with Indivior and Ultrahuman, reflect deepening partner engagement in development and commercialization. These alliances have produced FDA-authorized products and structured milestone and royalty pathways that reinforce external validation.

Product Line Growth: Multiple FDA authorizations (Rejoyn for MDD and CT-132 for migraine), the acquisition of AspyreRx, and an expanded pipeline spanning psychiatry, neurology, and cardiometabolic disease point to a broader, more mature portfolio. Positive Phase 3 results and commercialization preparations for CT-155 add momentum to this expansion.

Product Line Growth: Growth across non‑COVID medicines such as Eliquis, Padcev, the Vyndaqel family, Lorbrena, Nurtec/Vydura and oncology biosimilars has been robust. Launched and acquired products are showing sustained double‑digit operational gains, adding meaningful momentum.

Resilient & Sustainable Growth: Excluding COVID products, the underlying portfolio delivered mid‑single‑digit operational growth in 2025 and continued at a similar pace in early 2026, more than offsetting part of the COVID‑related decline. Reported revenue also returned to modest year‑over‑year growth in the first half of 2026, indicating stabilization.

Future-Ready Strategy: Management raised the midpoint of 2026 revenue guidance and continues to invest heavily in a broad late‑stage pipeline. This posture signals confidence that newer launches and acquired assets can drive the next leg of growth.

Strong Revenue Growth: Recent results indicate total revenue increased year over year in 2025 and continued to rise in the latest reported quarter. Guidance and quarterly updates point to ongoing top-line expansion even as mix shifts occur.

Resilient & Sustainable Growth: Underlying annual contract value expanded and accelerated in 2026, with management indicating continued growth despite the transition to hosted licensing. This suggests the core subscription base is strengthening even when reported revenue timing varies.

Diversified Revenue Streams: Growth is visible in both the software business and the milestone-driven drug discovery segment. The latter stepped up meaningfully in recent periods, complementing steady software momentum.

Market Expansion: The platform’s footprint expanded from 400 participating sites in 2022 to 6,000+ sites by 2026, with presence across 50+ countries and 25+ sponsors. Evidence indicates marketplace adoption more than doubled in 2023 and activity surpassed 100 trials by 2024.

Product Line Growth: The offering broadened from a marketplace into AI-powered patient pre-screening and integrated workflows, with reported operational time savings and enrollment improvements in case studies. Subsequent integrations with CRIO, RealTime eClinical, and eClinPro signal continued platform expansion.

Strategic Partnerships: Relationships include major pharmaceutical organizations (e.g., 16 of the top 30 in 2024 and now 25+ sponsors) and ecosystem deals such as RealTime eClinical (50+ networks representing 2,000+ sites) plus CRIO/eClinPro integrations. These ties appear to extend distribution and enrich data used for site selection and enrollment.

Strong Revenue Growth: Revenue is rising at double-digit rates across recent periods, and management has increased full-year guidance, underscoring continued momentum. Growth is visible in both recent quarters and the prior year, indicating sustained top-line expansion.

Diversified Revenue Streams: Both Diagnostics and Data & Applications are expanding, with data-licensing/Insights activity increasing alongside clinical testing volumes. This mix reduces reliance on a single line of business and supports multiple growth vectors.

Strategic Partnerships: Collaborations with major biopharmaceutical companies and broader rollouts of platforms such as Next signal expanding commercial reach. Announced initiatives like a large whole‑genome dataset and work with firms including Merck reinforce external demand for the platform.

Market Expansion: International footprint is described as rapidly scaling, with the oncology research network tripling year over year and later noted as nearly 70% ex‑U.S. growth across the UK, Germany, Japan, and new regions like Scotland. Point‑of‑care reach is also portrayed as expanding, with 1,600+ sites of care and increases from earlier baselines.

Product Line Growth: New offerings include the launch of Flatiron Telescope and multiple AI-enabled datasets, alongside expansions of major assets such as the NSCLC Panoramic dataset. Additional capabilities like LLM-based data extraction and new hematology datasets indicate broader, monetizable product breadth.

Strategic Partnerships: Collaborations are highlighted with organizations such as NCCN, Quest Diagnostics, Candid Health, TailorMed, and DeepScribe, as well as a multi‑year partnership alongside the Paradigm transaction. Engagements with 20+ global oncology drug developers and academic institutions reinforce a partnership‑driven operating model.

Investor Backing & Capital Strength: Capital raising has accelerated, including a $372M Series D in 2024 with total funding reported in the hundreds of millions to expand the pipeline and AI platform. Valuation has stepped up from roughly $1.04B (2021) to about $1.48B post‑money (2024), signaling strengthened private‑market positioning.

Strategic Partnerships: Partnerships are expanding, highlighted by a collaboration with Sanofi and OpenAI to build AI software for drug development and increased business‑development capacity via Entrepreneurs in Residence. Engagements with large pharma partners, including Sanofi, underscore growing external validation and deal flow.

Product Line Growth: The pipeline is broadening through multiple in‑licenses—such as an anti‑CD226 program, a CNS‑penetrant TYK2 inhibitor, and a miR‑124 activator—and progression to first‑in‑human dosing of BLKR201 in 2026. Stated plans to reach 10–15 assets over 3–5 years align with recent portfolio expansion and clinical advancement.

Strong Market Position & Advantage: Carvykti is positioned as the first and only BCMA‑targeted therapy approved as early as second line in the U.S./EU with overall‑survival data reflected on label, and commercial uptake has outpaced Abecma in the BCMA CAR‑T segment. Market updates cite thousands of patients treated and describe the product as a current standard‑setter within BCMA CAR‑T for multiple myeloma.

Strong Revenue Growth: Revenue and CARVYKTI sales have scaled rapidly through 2024–2025, with FY2024 revenue roughly $627M (up sharply year over year) and CARVYKTI net trade sales around $963M in 2024 followed by sequential increases in 2025. Collaboration revenue tied to CARVYKTI also rose significantly as availability and demand expanded.

Strategic Partnerships: The J&J collaboration underpins global development and commercialization while additional manufacturing collaboration with Novartis and capacity build‑outs in Belgium and the U.S. support supply. A licensing deal with Novartis for a DLL3 CAR‑T program further validates the platform and broadens modality reach.

Market Expansion: Recent announcements describe expansion of early‑phase clinical capabilities in 2026 alongside new and enlarged sites in Exton, Pennsylvania and Europe, indicating broader geographic reach and capacity. Acquisitions and a rising backlog/future contracted revenue further point to continuing expansion into additional markets and regions.

Product Line Growth: New GMP CRDMO capacity came online with a 46,300‑sq‑ft facility opened in 2025 and fully validated by late 2025, adding nine GMP suites and related labs. The 2026 acquisition of a CAP‑accredited central lab in China and added early‑phase clinical capabilities broaden the service portfolio.

Strong Revenue Growth: Recent interim results show first‑half 2026 revenue up 17.1% year over year with net profit more than doubling, signaling a rebound from prior softness. Purchase orders/backlog also increased versus prior periods, supporting near‑term top‑line momentum.

Investor Backing & Capital Strength: An upsized June 2026 IPO around $400M, alongside earlier large private rounds, indicates substantial capital access and investor appetite. Proceeds are framed for team expansion and advancing late-stage clinical programs.

Product Line Growth: Multiple late-stage cardiovascular programs and positive March 2026 Phase 2 data for tonlamarsen demonstrate pipeline momentum. Company materials and conference publications describe progressing assets with upcoming readouts.

Strong Hiring & Retention: Numerous current openings across clinical, data/AI, medical, regulatory, legal, and finance functions point to active headcount expansion. Listings on LinkedIn, Greenhouse, and the company’s careers page reinforce sustained recruitment.